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Abstract
Alzheimer’s disease is characterized by b-amyloid plaques and tau
tangles. Plasma levels of phospho-tau217 (P-tau217) accurately
differentiate Alzheimer’s disease dementia from other dementias,
but it is unclear to what degree this reflects b-amyloid plaque
accumulation, tau tangle accumulation, or both. In a cohort with
post-mortem neuropathological data (N = 88), both plaque and
tangle density contributed independently to higher P-tau217, but
P-tau217 was not elevated in patients with non-Alzheimer’s
disease tauopathies (N = 9). Several findings were replicated in a
cohort with PET imaging (“BioFINDER-2”, N = 426), where b-
amyloid and tau PET were independently associated with P-
tau217. P-tau217 concentrations correlated with b-amyloid PET
(but not tau PET) in early disease stages and with both b-amyloid
and (more strongly) tau PET in late disease stages. Finally, P-
tau217 mediated the association between b-amyloid and tau in
both cohorts, especially for tau outside of the medial temporal
lobe. These findings support the hypothesis that plasma P-tau217
concentration is increased by both b-amyloid plaques and tau
tangles and is congruent with the hypothesis that P-tau is involved
in b-amyloid-dependent formation of neocortical tau tangles.
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Introduction
b-amyloid (Ab) pathology and tau pathology are core hallmarks of
Alzheimer’s disease (AD). The amyloid cascade hypothesis states
that altered Ab metabolism is an initiating event, which drives accu-
mulation of aggregated tau (Sperling et al, 2014). These events are
associated with altered levels of fluid biomarkers, as has been exten-
sively studied in both cerebrospinal fluid (CSF) and plasma (Olsson
et al, 2016; Hampel et al, 2018). Recently, it has been shown that
plasma levels of hyperphosphorylated tau (including both P-tau181
(Janelidze et al, 2020; Karikari et al, 2020) and P-tau217 (Palmqvist
et al, 2020)) are markedly elevated in patients with AD. Plasma P-
tau217 levels have particularly high accuracy for AD and are corre-
lated with tangle densities in post-mortem data (Palmqvist et al,
2020). However, recent studies have suggested that CSF P-tau217
(and other P-tau variants) can be increased as a function of Ab accu-
mulation (Suarez-Calvet et al, 2020), also in individuals who are
tau-negative as determined by positron emission tomography (PET)
(Barthelemy et al, 2020b; Mattsson-Carlgren et al, 2020) (but note
that tau PET has limited sensitivity to detect very sparse tau aggre-
gation (Fleisher et al, 2020)). It is unclear to what degree plasma P-
tau217 levels depend on Ab versus tau load in the brain. Here, we
set out to clarify this question in two cohorts, including a cohort
with post-mortem quantification of Ab plaques and tau tangles, and
a large prospective cohort where Ab and tau load were measured
in vivo using PET imaging. In sum, we found converging evidence
from both cohorts that Ab and tau load had independent and inter-
active effects on plasma P-tau217. We also found that plasma P-
tau217 levels statistically mediated the effect of Ab load on tau load.
Finally, we found that in subjects with very limited tangle pathol-
ogy, Ab plaque load but not medial temporal lobe tangle load
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remained statistically associated with plasma P-tau217. Taken
together, the data from this observational study support the theory
that the first increases in release and phosphorylation of soluble tau
measured in plasma are driven by Ab aggregation and may appear
largely before spread of tau tangles outside of the medial temporal
lobe. One possibility is that soluble P-tau217 plays a role in the
spread of neocortical tangles, which could motivate trials with treat-
ments targeting soluble phosphorylated tau, to break the link
between Ab and tau aggregation in AD.
Results
Plasma P-tau217 is independently associated with pathology
measures of both Ab and tau
We first tested associations between antemortem plasma P-tau217
and neuropathological quantification of Ab plaques and tau tangles
in a cohort with post-mortem data (N = 88). We compared regres-
sion models with plasma P-tau217 as response variable and dif-
ferent sets of predictors, including I) only Ab plaque density, II)
only tau tangle density, III) both Ab plaque and tangle densities,
and IV) Ab plaque and tangle densities and their interaction. All
models included age and sex as covariates. For the individual
models, the tangle only model had slightly higher overall explana-
tory power (R2 = 0.47) than the plaque only model (R2 = 0.40)
(DAIC = 9 favoring the tangle only model, but the difference in R2
was not significant, tested in a bootstrap procedure, DR2 = 0.07,
95% CI 0.17 to 0.25). Model comparisons favored including both
plaques and tangle densities in an interaction model (Fig 1A,
DAIC = 5-29 compared to the other models). In the interaction
model, both plaque density (b = 2.00, P < 0.0001; compared to
b = 2.95, P < 0.0001 in the plaque only model) and tangle density
(b = 1.46, P = 0.0072; compared to b = 3.29, P < 0.0001 in the
tangle only model) and the plaque by tangle interaction (b = 1.26,
P = 0.012) were significantly associated with higher plasma P-
tau217 levels. Age (P = 0.19) and sex (P = 0.59) were non-
significant in the interaction model. Higher plaque density had the
strongest association with high plasma P-tau217 among those with
higher tangle density (visualized with tertiles of tangles in Fig 1B),
and higher tangle density had the strongest association with high
plasma P-tau217 among those with higher plaque density (visual-
ized with tertiles of plaques in Fig 1C). For all these analyses,
plaque and tangle densities were used as continuous variables,
centered, and scaled to z-scores. These results supported the
hypothesis that plasma P-tau217 is increased by independent effects
of both Ab and tau pathology.
Plasma P-tau217 statistically mediates the effect of Ab on tau
We next conducted statistical mediation analyses in the
neuropathology cohort (Fig 2). Plasma P-tau217 partly mediated the
effect of Ab plaque density on tau tangle density (but Ab plaque
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Figure 1. Independent effects of plaque and tangle density on plasma P-tau217.
A R2 and AIC for different regression models, using either only amyloid plaque density (“P”), only tangle density (“T”), both plaque and tangle density (“P + T”), or both
plaque and tangle density including their interaction term (“PxT”). All models included age and sex as covariates. The panel shows adjusted R2, together with AIC
(above the bars) for each model. We compared R2 between the models using a bootstrap procedure (N = 1,000 iterations), which showed that the R2 for the “PxT”
model was marginally higher than for the “P + T” model (DR2 = 0.027, 95% CI 0.0034-0.087) and significantly higher than for the “T” model (DR2 = 0.12, 95% CI
0.04-0.24) and the “P” model (DR2 = 0.18, 95% CI 0.055-0.31).
B Associations between plasma P-tau217 and plaque density (stratified by tertiles [T1-3] of tangle density).
C Associations between plasma P-tau217 and tangle density (stratified by tertiles [T1-3] of plaque density).
Data information: Tertiles were chosen to visualize the data in panels (B, C), but the regression models used continuous density data as predictors. The solid lines
represent mean effects from regression models. The shaded areas are 95% confidence intervals for the mean effects. Samples were analyzed in duplicates.
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the presence of plasma P-tau217) (60% mediation, Fig 2A). In
contrast, there was no significant mediation of effects of Ab plaque
density on tau tangle density in the medial temporal lobe (entorhi-
nal cortex and hippocampus) (the direct effect of Ab plaques on tau
tangles was also weaker, Fig 2B). The strongest mediation was seen
for total tangle density when removing tangles in the medial tempo-
ral lobe (77% mediation; the direct effect of Ab plaques on tangles
became non-significant, Fig 2C). These results suggest that plasma
P-tau217 may partly explain the link between build-up of Ab and
tau pathology, especially for tau pathology that extends over the
neocortex, beyond the medial temporal lobe.
No associations between plasma P-tau217 and isolated medial
temporal lobe tau
To study the effects of very subtle tau pathology on plasma P-
tau217, we did a subset analysis on the neuropathology cohort
participants without tangles in the parietal or frontal lobe (and only
minimal tangle pathology in the temporal lobe, allowing score 0.5,
indicating a density halfway between “none” [0] and “sparse” [1])).
In this subset (N = 42), Ab plaque density remained significantly
associated with plasma P-tau217 (b = 1.64, P < 0.0001) (Fig 3A),
but medial temporal lobe tangles were not associated with plasma
P-tau217 (P = 0.40, Fig 3B) and there was no association between
Ab plaque density and medial temporal lobe tangle density
(P = 0.59, Fig 3C). These results suggest that Ab pathology is linked
to increased phosphorylation and/or release of tau even in very
early stages of AD (without prominent tangle pathology in the
neocortex). In contrast, tau pathology which is contained in the
medial temporal lobe without significant neocortical involvement
appears to possibly occur independently of Ab pathology and with-
out altered phosphorylation or release of soluble tau.
No associations between plasma P-tau217 and primary
tauopathies (CBD and PSP)
To test whether plasma P-tau217 was elevated in individuals with a
primary non-AD tauopathy, we performed a sensitivity analysis that
included nine additional subjects with neuropathology data and a
primary neuropathological diagnosis of PSP (N = 7) or CBD (N = 2)
(7 females/2 males; mean age [SD] at death: 87 [8.7] years; mean
time between sample collection and death: 1.1 [0.75] years). These
were included from the same neuropathology program as the main
pathology cohort. Figure 4 shows plasma P-tau217 (Fig 4A),
plaque density (Fig 4B), and tangle density (Fig 4C) for these
subjects and (for comparison) for subjects with no significant
primary pathology, AD, Parkinson’s disease, or other primary
pathologies. PSP/CBD subjects had low plasma P-tau217 (no dif-
ference compared to subjects without significant primary pathology;
P = 0.66, Mann–Whitney U-test). Further, they also had low plaque
density (no difference compared to subjects without significant




Figure 2. Plasma P-tau217 mediates effects of plaques on tangles.
A–C Three different mediation models are shown, testing plasma P-tau217 as a statistical mediator of plaque density on tangle density. Panel (A) shows the mediation
of total tangle density (significant mediation, 60% of the direct effect of plaque density on tangle density was explained by plasma P-tau217). Panel (B) shows the
mediation of medial temporal lobe (MTL, entorhinal cortex and hippocampus) tangle density (no mediation). Panel (C) shows the mediation of tangle density in all
regions except the MTL (strongest mediation, 77%). The P-values are from linear regression models used to estimate the mediation effects.
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(higher levels compared to subjects without significant primary
pathology, P = 0.068; no difference compared to AD, P = 0.37). This
suggests that plasma P-tau217 is not necessarily elevated due to tau
accumulation in pure non-AD tauopathies, supporting that the
increase in plasma P-tau217 is specific to AD (and may require
plaque deposition in addition to tau accumulation).
Plasma P-tau217 is independently associated with PET measures
of both Ab and tau
We next tested associations between plasma P-tau and measures of
aggregated Ab and tau in vivo in the BioFINDER-2 cohort (see

























































MTL tangles ~ PlaquesC
Figure 3. Associations between plasma P-tau217, Ab plaque density, and medial temporal lobe (MTL) tangle density in people with limited tau pathology.
A–C Individuals in the neuropathology cohort without tangles in the parietal or frontal lobe and no more than minimal tangle load in the temporal lobe were included
in this analysis (N = 42). MTL tangles were defined as tangles in entorhinal cortex plus hippocampus. Relationships between variables were tested in linear
regression models, adjusted for age and sex. In these models, plasma P-tau217 was significantly associated with Ab plaques (b = 1.64, P < 0.0001) (panel A) but
not with MTL tangles (panel B). MTL tangles were not associated with Ab plaques (panel C). The solid line in panel (A) is the mean effect from the regression model,
































































































Figure 4. Plasma P-tau217, Ab plaque density, and tau tangle density by primary neuropathology.
A–C Individuals in the neuropathology cohort were divided into groups of no significant primary pathology (N = 31), AD (N = 36), PD (N = 13), and others (N = 8) and
analyzed together with N = 9 additional subjects with primary non-AD tauopathies (PSP/CBD). Data are shown for plasma P-tau217 (panel A), plaque density
(panel B), and tangle density (panel C). Plasma P-tau217 was not elevated in PSP/CBD compared to subjects without significant primary pathology. AD, Alzheimer’s
disease; CBD, corticobasal degeneration; PSP, progressive supranuclear palsy; and PD, Parkinson’s disease. The central band of the boxes is medians, and the boxes
show interquartile ranges. The whiskers are defined as the smallest (largest) observation greater (less) than or equal to the first (third) quartile minus (plus) 1.5
times the interquartile range.
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P-tau217 as response variable and different sets of predictors,
including I) only Ab PET (using a large cortical region-of-interest
[ROI]), II) only tau PET (using a global cortical ROI representing
Braak stages I-VI), III) both Ab PET and tau PET, and IV) Ab PET
and tau PET and their interaction. Model comparison of adjusted R2
and AIC favored the model with the interaction term over the other
models (Fig 5A). In the interaction model, both Ab PET (b = 1.07,
P < 0.0001) and tau PET (b = 0.44, P < 0.0001) and the Ab by tau
PET interaction (b = 0.31, P < 0.0001) were significantly associated
with greater plasma P-tau217 (Ab and tau PET were used as contin-
uous variables, centered, and scaled to z-scores). Age (P = 0.89)
and sex (P = 0.91) were non-significant predictors in the model.
Higher Ab PET was associated with higher plasma P-tau217 at all
levels of tau PET (with strongest association in those with highest
tau PET) (Fig 5B). Higher tau PET was associated with higher
plasma P-tau217 in those with high (but not in those with low) Ab
PET (Fig 5C) (but we acknowledge that the narrow range of tau PET
in the individuals with low Ab PET makes it more difficult to detect
a significant association with plasma P-tau217, compared to in those
with high Ab PET, where the range of tau PET is wider). These
results largely agreed with our results from the neuropathology
dataset, showing that plasma P-tau217 is independently related to
both Ab and tau build-up.
Plasma P-tau217 correlations with Ab and tau PET stratified by
Ab and tau positivity
The finding that P-tau217 was independently related to both
neuropathological densities of plaques and tangles, as well as both
Ab and tau PET measures, led us to the hypothesis that plasma P-
tau217 mainly reflects Ab pathology during the early stages of the
disease (prior to significant neocortical spread of tangles), but is
more closely related to tau pathology during the later stages of the
disease (when both Ab and tau pathologies are widespread). To test
this hypothesis in vivo, we grouped the BioFINDER-2 participants
into three groups: negative for both Ab PET and tau PET (N = 264),
Ab PET-positive but tau PET-negative (N = 104), and positive for
both Ab and tau PET (N = 58). For this grouping, we used the tau
PET uptake in a neocortical ROI corresponding to Braak regions I-IV
(Leuzy et al, 2020). No individual in this dataset had negative Ab
PET combined with positive tau PET. Figure 5 (panels D-I) shows
correlations between plasma P-tau217 and Ab PET (Fig 5D–F) and
tau PET (Fig 5G–I). There were no correlations between plasma P-
tau217 and either Ab or tau PET in the Ab- and tau-negative group
(P > 0.05, Fig 5D and 5G). In those with isolated Ab positivity,
plasma P-tau217 correlated with Ab PET (P < 0.001, although the
explanatory power of Ab on plasma P-tau217 was modest,
R2 = 0.10, Fig 5E) but not tau PET (P = 0.92, R2 = 0, Fig 5H). In the
group positive for both Ab and tau, plasma P-tau217 correlated with
both Ab PET (R2 = 0.14 for Ab, Fig 5F) and tau PET (R2 = 0.46 for
tau, Fig 5I) but had strongest correlation with tau PET. This
supported our hypothesis that plasma P-tau217 reflects both Ab and
tau accumulation in AD, but primarily reflects Ab accumulation
during the early disease stages (when tau PET is still negative) and
Table 1. Demographics
Arizona neuropathology cohort BioFINDER-2
N 88 426
Men/female 35/53 227/199
Age 83.7 (8.1) 65.7 (13.7)
Diagnostic
group




264 Ab- CU (MMSE
29.0 [1.2])
73 Ab+ CU (MMSE
28.6 [1.4])
81 Ab+ MCI (MMSE
26.5 [2.0])




e2/e3 N = 8
e2/e4 N = 2
e3/e3 N = 49
e3/e4 N = 26
e4/e4 N = 3
e2/e2 N = 2
e2/e3 N = 24
e2/e4 N = 10
e3/e3 N = 182
e3/e4 N = 180
e4/e4 N = 28
Continuous data are mean (standard deviation). Mini-Mental State
Examination (MMSE) score is provided for the different diagnostic groups.
NIA-Reagan refers to the National Institute on Aging-Reagan Institute criteria
for the neuropathological diagnosis of Alzheimer disease (Hyman &
Trojanowski, 1997). CU, cognitively unimpaired. MCI, mild cognitive
impairment. AD, Alzheimer’s disease.
▸Figure 5. Associations between plasma P-tau217 with Ab PET and tau PET.A R2 and AIC for different regression models, using either only Ab PET (“A”), only tau PET (“T(I-VI)”), both Ab and tau PET (“A + T”), or both Ab and tau PET
including their interaction term (“AxT”). All models included age and sex as covariates. The panel shows adjusted R2, together with AIC (above the bars) for
each model. We compared R2 between the models using a bootstrap procedure (N = 1,000 iterations), verifying that the R2 for the “AxT” model was higher
than for the “A + T” model (DR2 = 0.026, 95% CI 0.010-0.058), the “T(I-VI)” model (DR2 = 0.17, 95% CI 0.11-0.26), and the “A” model (DR2 = 0.14, 95% CI
0.060–0.22).
B Associations between plasma P-tau217 and Ab PET stratified by tertiles (T) of tau PET (T1: SUVR ≤ 1.05, T2: 1.05 < SUVR ≤ 1.11, T3: 1.11 < SUVR ≤ 3.03).
C Associations between plasma P-tau217 and tau PET stratified by tertiles (T) of Ab PET (T1: SUVR ≤ 0.468, T2: 0.468 < SUVR ≤ 0.579, T3: 0.579
< SUVR ≤ 1.08).
D–I Associations with P-tau217 across groups of Ab and tau PET positivity. Cut-points for Ab PET (> 0.533 SUVR) and tau PET (> 1.36 SUVR in a ROI corresponding to
Braak stages I-IV) were used to define the groups. Associations are shown for global cortical Ab PET (panels D-F) and global cortical tau PET (corresponding to Braak
stages I-VI) (panels G-I) in individuals classified as negative for both Ab and tau (N = 264, panels D and G), positive for Ab only (N = 104, panels E and H), or
positive for both Ab and tau (N = 58, panels F and I). The plots show R2 and P-values from linear regression models. No covariates were included in these models, in
order to generate R2-values for the PET measures alone.
Data information: In panels (B, C), tertiles were chosen to visualize the data, but the regression models used continuous PET uptake as predictors. In panel (C), one
outlier was beyond the range of the x-axis (plasma P-tau217 = 17.8 ng/L, tau PET = 3.03 SUVR, 3rd Ab PET tertile). The solid lines represent mean effects from regression
models. The shaded areas are 95% confidence intervals for the mean effects. Samples were analyzed in duplicates.
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primarily tau accumulation during the later disease stages (when
both Ab and tau PET are positive).
Plasma P-tau217 statistically mediates effects of Ab PET on
tau PET
We also conducted statistical mediation analyses to test to what
degree plasma P-tau217 explained effects of Ab aggregation on tau
uptake in BioFINDER-2. Plasma P-tau217 partly mediated the effect
of Ab PET on global tau PET (63% mediation, Fig 6A). The media-
tion was attenuated for tau PET in the medial temporal lobe (en-
torhinal cortex and hippocampus, 29%, Fig 6B). This is consistent
with the hypothesis that the mechanism that links Ab build-up to
tau aggregation involves increased phosphorylation and/or release
of soluble tau, and that this is especially important for tau aggrega-
tion that occurs outside of the medial temporal lobe (entorhinal
cortex and hippocampus).
Discussion
With recent advances in assay development, it is now possible to
measure plasma levels of P-tau217 in clinical research, drug trials,
and perhaps also in clinical practice in the future. To best interpret
the P-tau217 results, it is important to understand what plasma P-
tau217 levels represent. Although proposed frameworks have
largely assumed that soluble P-tau best mirrors tau deposition (Jack
et al, 2018), we and others have previously noted that CSF P-tau
may be increased also as a function of Ab deposition (Barthelemy
et al, 2020b; Mattsson-Carlgren et al, 2020)—i.e., provide an
indicator of Ab-related tau pathophysiology that anticipates the
development of measurable tau tangle pathology. We therefore
hypothesized that plasma P-tau217 levels would be related to both
Ab and tau aggregation. Supporting our hypothesis, we found that
both Ab plaques and tau tangles were independently associated with
higher plasma P-tau217 levels, when measured both post-mortem
by neuropathological quantification (providing the most sensitive
indicator of tau tangle deposition) and in vivo by PET imaging
(which may not detect tau tangles until there is more substantial
and spatially extensive tangle deposition). Ab plaques and tau
tangles also interacted, so that highest plasma P-tau217 levels were
seen in individuals who had high levels of both Ab plaques and tau
tangles. The independent effects of Ab load and tau tangle load on
plasma P-tau217 were significant, with considerable increases in
model R2 when combining Ab and tau predictors compared to when
using just one of them alone. Even though the results were mainly
similar when using either post-mortem neuropathology examination
or in vivo PET imaging to detect tau tangles, we found that plasma
P-tau217 was more strongly associated with tau tangles than Ab
plaques when using neuropathology examination, which was not
the case when using PET (compare Fig 1A with Fig 5A). This is
probably explained by the fact that tau PET imaging does not reli-
ably detect lower amounts of tau aggregates in the brain, as shown
in a recent end-of-life study by Fleischer et al evaluating the diag-
nostic performance of 18F-flortaucipir (Fleisher et al, 2020).
However, even when using neuropathology examination, Ab pathol-
ogy had an independent effect on plasma P-tau217 levels, and in
cases with more limited tau pathology (mainly restricted to the
medial temporal lobe), plasma P-tau217 correlated with Ab pathol-
ogy but not tau tangles, although we acknowledge that the methods
used for tau quantification in the brain may not be sensitive to the
earliest most subtle tau aggregation (Fig 3) (and since the total
amount of aggregated tau is low in subjects with tau tangles limited
to the medial temporal cortex, it is more difficult to detect an associ-
ation between tangle load and plasma P-tau217 in those individuals
compared to when tangles have also spread into neocortex). These
results are congruent with recent studies showing that both blood
and CSF P-tau217 are associated with Ab PET also in tau PET-
negative cases (Mattsson-Carlgren et al, 2020; Janelidze, 2021).
Together, these results imply that plasma P-tau217 is not associated
with tau tangle pathology independent from Ab pathology, includ-
ing primary age-related tauopathy (PART, see Fig 3B) (Sperling
et al, 2014). However, plasma P-tau217 is associated with Ab
pathology, even during the early stages of the disease (Fig 3A), and
it is further strongly associated with more widespread tau tangles in
cases with Ab pathology (Figs 1C and 4C). More research is needed
to understand the molecular and cellular mechanisms behind how
early Ab pathology leads to changes in extracellular P-tau217 levels.
A B
Figure 6. Mediation analyses in BioFINDER-2.
A, B Plasma P-tau217 partly mediated the effect of Ab PET on tau PET, when using tau PET quantified in Braak stages I-VI (A, “Tau PET global”, 66% of the direct effect
of Ab PET on tau PET was explained by plasma P-tau217) or in the medial temporal lobe (B, MTL, entorhinal cortex and hippocampus, 29%). The P-values are from
linear regression models used to estimate the mediation effects.
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Overall, the link between Ab pathology and increased plasma P-
tau217 is in line with recent results from cell models (Kwak et al,
2020) showing that phosphorylation of tau is increased in the pres-
ence of Ab.
Plasma P-tau217 also provided statistical mediation for the
effects of Ab load on tau load in both the neuropathology dataset
and the BioFINDER-2 PET imaging dataset. Intriguingly, the media-
tion effect of P-tau217 was especially strong for neuropathological
quantification of tangle burden in the neocortex (excluding tangle
count densities in entorhinal cortex and hippocampus, Fig 2C),
where plasma P-tau217 explained up to 77% of the effect of Ab
plaques on tangle burden and the direct effect of Ab plaques on
tangles became non-significant when correcting for P-tau217. The
in vivo measures with Ab and global tau PET showed similar results,
with considerable statistical mediation for plasma P-tau217 on global
tau PET (66%), but less mediation (29%) when using tau PET quan-
tified in the entorhinal cortex or hippocampus. This shows that
plasma P-tau217 may be especially important for the spread of tau
outside of the medial temporal lobe. Isolated medial temporal lobe
tangle pathology (which may even appear in the absence of Ab
pathology, including “PART” (Crary et al, 2014)) appears not to be
strongly related to increased phosphorylation and/or secretion of tau.
When grouping the subjects into three hypothetical “disease
stages” (Fig 6), we found no correlations between plasma P-tau217
and either Ab PET or tau PET in those that were negative for both
Ab and tau PET (we consider these individuals to not have AD),
significant correlations to Ab PET (but not tau PET) in those who
were within the positive range for Ab PET only (we consider this an
early stage of AD), and significant correlations to both Ab PET and
tau PET (but strongest with tau PET) in those who were positive for
both Ab and tau PET (we consider this a later stage of AD). Taken
together, these findings are congruent with the hypothesis that Ab
pathology leads to an increased release of soluble P-tau, which in
turn is associated with a spread of tau tangle pathology beyond the
medial temporal lobe. Figure 7 shows a hypothetical model which
integrates the findings from this study and previous studies on
biomarkers and development of AD. However, we note that dif-
ferent sensitivities of the biomarkers to detect underlying patholo-
gies could impact their correlations. One possibility is that plasma
P-tau217 may reflect AD-related tau hyperphosphorylation earlier
and with higher sensitivity than tau PET. Alternatively, the plasma
P-tau217 may initially increase due to increased site phosphoryla-
tion at 217 in the Ab growth stage, and then as soluble total tau
concentrations increase later, the P-tau217 increases further, but
without specific increases in phosphorylation at site 217
(Barthelemy et al, 2020a, 2020b). Additional valuable information
could come from Ab overproducing mouse models that do not
develop tau tangles, to characterize the extent to which Ab could
promote tau secretion even in the absence of subsequent tau tangle
deposition (Maia et al, 2015; Mattsson-Carlgren et al, 2020).
Over the last years, there has been an increased interest in anti-
tau treatments for AD (Bittar et al, 2020). One hypothetical possibil-
ity raised by our results is that therapies targeting the processes that
lead to production of P-tau217 may break the link between build-up
of aggregated Ab and tau and thereby reduce atrophy and cognitive
decline in AD (which are both strongly associated with tau pathol-
ogy (Mattsson et al, 2019; Ossenkoppele et al, 2019)). At least one
tau-directed treatment (using an anti-tau antibody) has been
Figure 7. Hypothetical integration of neuropathology, fluid biomarker, and PET imaging findings.
The figure shows hypothetical pathways, supported by our results, which link deposition of Ab pathology to development of neocortical tangles through increased
phosphorylation and/or release of soluble tau. We also include a hypothetical feedback loop, where tangle pathology also may drive increased levels of soluble P-tau,
possible due to tau propagation between affected neurons. We also acknowledge that other alternative explanations may be considered for our findings. One possibility
is that lack of sensitivity of our methods to accurately quantify aggregated tau makes us unable to detect very early associations between aggregated tau and plasma P-
tau217.
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reported to reduce CSF levels of P-tau217 (conference presentation
by Michael Fresser at AAT-AD/PD 2020). Further drug development
may incorporate plasma P-tau217 data in early stages to select drug
candidates most likely to have beneficial effects on the biochemistry
of tau in the brain in AD.
A limitation of this study is the relatively small dataset in the
neuropathology cohort, with a very wide spread of different
pathologies. Especially, there were quite few study participants with
intermediate plaque counts (most had either very few plaques or
substantial plaque pathology). Larger neuropathology datasets
would be valuable to validate the findings directly in post-mortem
material. We used the large BioFINDER-2 cohort to validate the find-
ings, but we acknowledge that tau PET has limited sensitivity for
early stage tau pathology (with isolated tangle pathology in entorhi-
nal cortex and hippocampus). We therefore refrained from doing
some of the subgroup analyses in BioFINDER-2 (focusing on MTL
tau in individuals with negative global tau). Another limitation is
that we used cross-sectional data, and longitudinal data for multiple
modalities are needed to strengthen hypotheses about causal rela-
tionships between the biomarkers.
In summary, plasma P-tau217 is independently associated with
both Ab plaques and tau tangles, including associations with Ab
pathology even in cases with restricted tau tangle pathology and
strong associations with tau tangles in Ab-positive cases.
Materials and Methods
Participants
Study participants were from two cohorts. First, we included
subjects from a biomarker-neuropathology cohort study (the
Arizona Study of Aging and Neurodegenerative Disorders/Brain and
Body Donation Program), also described previously (Palmqvist
et al, 2020). Second, we included subjects from the prospective
cohort study BioFINDER-2 (clinical trials: NCT03174938), explained
previously (Palmqvist et al, 2020). From BioFINDER-2, we included
all available cognitively unimpaired controls, Ab+ mild cognitive
impairment (MCI), and Ab+ AD dementia patients (where Ab+ was
determined by Ab PET, explained below) with Ab and tau PET data.
Study demographics are summarized in Table 1. The data used for
this paper partly overlap with data in a previous publication in diag-
nostic performance of plasma P-tau217 (Palmqvist et al, 2020) (but
the BioFINDER-2 sample used here is more restricted, since both Ab
and tau PET were required for inclusion in this study). Informed
consent was obtained from all study participants.
Fluid biomarkers
Plasma P-tau217 was measured using immunoassays at Lilly
Research Laboratories, as described before (Palmqvist et al, 2020).
In the Arizona Study of Aging and Neurodegenerative Disorders/
Brain and Body Donation Program, the mean (standard deviation)
time between plasma collection and death was 1.2 (0.8) years. In
BioFINDER-2, the mean time between plasma collection and PET
imaging was 0.16 (0.22) years. Plasma P-tau217 data were not avail-
able to assessors of neuropathology or neuroimaging (minimizing
subjective bias).
Neuropathology
We included subjects from the biomarker-neuropathology cohort with
or without neuropathological evidence of AD. Ab plaque and
neurofibrillary tangles were graded at standard sites in frontal, tempo-
ral, parietal, occipital cortices, the hippocampal CA1 region, and
entorhinal/transentorhinal cortex, using 80-lm sections (Palmqvist
et al, 2020). Plaque densities (including cored, neuritic, and diffuse
plaques together) were derived using the Campbell–Switzer staining.
Neurofibrillary tangle densities were derived using three staining
methods (thioflavin S, Campbell–Switzer, and Gallyas) on the same
sections. The CERAD templates (Mirra et al, 1991) were used to obtain
semi-quantitative regional scores for Ab and tangle pathology, which
were summed to total plaque and tangle scores (range 0-15). All
histopathological scoring was blinded to clinical or neuropathological
diagnosis (see Table EV1 for details) and to biomarker levels.
PET imaging
The procedures of tau PET (using RO948 labeled with radioactive fluo-
rine [18F]) and Ab PET (using flutemetamol labeled with 18F) have
been described previously (Palmqvist et al, 2020). Ab PET was
sampled in a global cortical ROI. When used as a dichotomous vari-
able, Ab PET > 0.533 SUVR was defined as a positive scan (defined
previously using mixture modeling (Palmqvist et al, 2020)). Tau PET
was sampled in different ROIs, corresponding to different Braak
regions. For most analyses, we used a large composite corresponding
to Braak regions I-VI, in order to comprehensively capture AD-related
brain tau pathology. For some analysis, we used a dichotomous vari-
able for neocortical tau PET positivity, using tau PET uptake in a more
limited ROI (corresponding to Braak stages I-IV, where tau PET > 1.36
SUVR was defined as a positive scan (Leuzy et al, 2020)).
Statistics
Associations between plasma P-tau217 and measures of Ab and tau
were tested in linear regression models, adjusted for age and sex. For
models in the neuropathology cohort, we also evaluated models
adjusted for the time between plasma sampling and death. This
covariate was never significant and did not alter the effects of the
other predictors and was therefore not included in the final models.
Different regression models were compared on the same subjects
and outcome, with different sets of predictors (including only Ab
data, only tau data, or both types of data, with or without an interac-
tion term). Models were compared using R2 and Akaike information
criterion (AIC, where a lower value indicates a better fit, corrected
for model complexity). Assumptions of regression models were
assessed by inspection of standard diagnostic plots. Bootstrap proce-
dures (N = 1,000 iterations) were used to compare R2 between
models. Mediation analyses were done to test the relationship
between Ab load, tau load, and plasma P-tau217 (using bootstrapped
estimates of mediation effects). Statistics were done in R (v 4.0.2).
Data availability
Anonymized data will be shared by request from a qualified
academic investigator and as long as data transfer is in agreement
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with EU legislation on the general data protection regulation and
decisions by the Ethical Review Board of Sweden and Region Skane,
which should be regulated in a material transfer agreement.
Expanded View for this article is available online.
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